Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 5/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898597 | 0.88 | PGD (0.42) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL14513716 | 0.84 | PGD (0.58) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL14513725 | 0.84 | PGD (0.58) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL26207056 | 0.80 | PGD (0.58) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL7328567 | 0.80 | PGD (0.58) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL4572660 | 0.79 | PGD (0.56) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL5959432 | 0.79 | PGD (0.56) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL17898551 | 0.75 | PGD (0.59) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL14513718 | 0.75 | PGD (0.59) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 | |
| SCHEMBL16688117 | 0.72 | PGD (0.51) | PGDLPAR3ENPP2LPAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | PGD 4383/4885LPAR3 1218/4885ENPP2 2279/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | PGD 4383/4885LPAR3 1218/4885ENPP2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.